Author: healthylife7

ByLucy Notarantonio Newsweek is a Trust Project member See more of our trusted coverage when you search.to see more of our trusted coverage when you search.

IMCD Group will exhibit its range of nine exclusive food and beverage concept creations, zeroing in on the e-sports category at IFT First 2026 in Chicago, US (July 12–15). The company highlights the segment as one of the fastest-growing digital markets, with consumers in the field seeking nutritional solutions that offer energy, performance, and engaging…

The Duke of Sussex went head-to-head with Alison Hammond in a laser shootout as the royal visited Birmingham to promote the Invictus Games

Investors seeking exposure to healthcare innovation often have to choose between the stability of established pharmaceutical giants and the higher-growth, higher-risk profile of clinical-stage biotech firms. This comparison looks at the two popular funds — the iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) and the iShares Biotechnology ETF (NASDAQ:IBB)– to see how their differing concentration, volatility, and…

According to the latest IndexBox report on the global Betamethasone Acetate market, the market enters 2026 with broader demand fundamentals, more disciplined procurement behavior, and a more regionally diversified supply architecture

Helen Mirren’s acting career spans six decades, seeing her jump from stage to screen while tackling a wide range of genres. But one thing has remained constant: her workout routine

For decades, career growth followed a familiar path. Employees joined as executives, became team leads, moved into middle management and climbed steadily towards senior leadership

Minister of Culture, Gender, Entertainment and Sport Oli the evening’s featured speakers

This is a paid press release. Contact the press release distributor directly with any inquiries.

The pressure on Amgen’s Tavneos is ratcheting up ahead of a potential hearing about the future of the drug. Since the FDA proposed withdrawing approval in April, a journal has retracted a key paper on the rare disease drug, the European Medicines Agency has recommended revoking authorization and Amgen’s Japanese partner has reportedly urged doctors…